APLS Apellis Pharmaceuticals Inc

Price (delayed)

$35.07

Market cap

$3.05B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.77

Enterprise value

$3.19B

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims ...

Highlights
APLS's net income is down by 28% since the previous quarter but it is up by 2.2% year-on-year
The EPS has declined by 25% since the previous quarter but it is up by 18% year-on-year
The equity has dropped by 161% year-on-year
The company's quick ratio has shrunk by 74% YoY and by 56% QoQ

Key stats

What are the main financial stats of APLS
Market
Shares outstanding
87M
Market cap
$3.05B
Enterprise value
$3.19B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
11.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.69
Earnings
Revenue
$251.27M
EBIT
-$431.39M
EBITDA
-$429.95M
Free cash flow
-$245.03M
Per share
EPS
-$5.77
Free cash flow per share
-$3.04
Book value per share
-$1.76
Revenue per share
$3.12
TBVPS
$8.68
Balance sheet
Total assets
$699.91M
Total liabilities
$841.41M
Debt
$409.63M
Equity
-$141.49M
Working capital
$497.34M
Liquidity
Debt to equity
-2.9
Current ratio
4.15
Quick ratio
3.81
Net debt/EBITDA
-0.32
Margins
EBITDA margin
-171.1%
Gross margin
100%
Net margin
-183.2%
Operating margin
-126.1%
Efficiency
Return on assets
-56.8%
Return on equity
-834.7%
Return on invested capital
-60.7%
Return on capital employed
-79.6%
Return on sales
-171.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APLS stock price

How has the Apellis Pharmaceuticals stock price performed over time
Intraday
11.69%
1 week
6.08%
1 month
-47.18%
1 year
13.97%
YTD
-38.69%
QTD
-44.51%

Financial performance

How have Apellis Pharmaceuticals's revenue and profit performed over time
Revenue
$251.27M
Gross profit
$251.27M
Operating income
-$316.77M
Net income
-$460.29M
Gross margin
100%
Net margin
-183.2%
APLS's operating margin is down by 33% since the previous quarter
APLS's operating income is down by 33% since the previous quarter but it is up by 19% year-on-year
APLS's net income is down by 28% since the previous quarter but it is up by 2.2% year-on-year
The company's net margin fell by 28% QoQ

Growth

What is Apellis Pharmaceuticals's growth rate over time

Valuation

What is Apellis Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
11.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.69
The EPS has declined by 25% since the previous quarter but it is up by 18% year-on-year
The equity has dropped by 161% year-on-year
The stock's price to sales (P/S) is 99% less than its last 4 quarters average of 895.8

Efficiency

How efficient is Apellis Pharmaceuticals business performance
APLS's ROE has shrunk by 195% YoY
The company's return on invested capital rose by 50% YoY but it fell by 40% QoQ
APLS's ROA is down by 35% since the previous quarter but it is up by 27% year-on-year
The return on sales has declined by 31% since the previous quarter

Dividends

What is APLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APLS.

Financial health

How did Apellis Pharmaceuticals financials performed over time
Apellis Pharmaceuticals's total assets is 17% less than its total liabilities
The company's quick ratio has shrunk by 74% YoY and by 56% QoQ
The company's current ratio has shrunk by 72% YoY and by 55% QoQ
The equity has dropped by 161% year-on-year
The debt to equity has dropped by 137% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.